Transcatheter Embolization and Occlusion Devices Companies

Latest Transcatheter Embolization and Occlusion Devices Companies Update

December 2022: Abbott commenced the provision of the Navitor Transcatheter Aortic Valve implantation (TAVI) system in India in December 2022. This product aims to address the medical needs of individuals afflicted with severe aortic stenosis, namely those categorized as high or extreme surgical risk patients. The firm is driving the progress of TAVI (transcatheter aortic valve replacement), generally referred to as TAVR, through innovations such as the development of the Navitor valve. Transcatheter aortic valve implantation (TAVI) is a viable option to surgical aortic valve replacement, offering potential relief from symptoms and increased longevity for those afflicted with this condition.

November 2022: Nyra Medical, Inc., a medical device company, made an announcement in November 2022 on the successful conclusion of a Series A financing round worth $20 million. The purpose of this funding is to provide assistance for the advancement of their innovative transcatheter mitral valve replacement technology. Broadview Ventures, Epidarex Capital, and the Georgia Research Alliance Venture Fund, with Vensana Capital and a prominent multinational medical equipment manufacturer, were the primary investors in the funding round. The funds generated will be allocated towards conducting clinical feasibility studies for Nyra's technological innovation. The Nyra (CARLEN) transcatheter device has been designed to address mitral regurgitation by replacing the native mitral valve leaflets with a distinct implant, while preserving the natural shape of the valve.

• Terumo Corporation


• Medtronic, Inc.


• Boston Scientific Corporation


• Stryker Corporation


• Cordis Corporation


• DePuy Synthes


• St. Jude Medical


• Cook Medical


• Sirtex Medical


• Nordion.